蛋白酪氨酸激酶抑制剂的进展与临床评价

目的：归结于药学和生物工程技术的进步,把对肿瘤细胞的攻击锁定于表皮生长因子和血管内皮生长因子等靶位,使药物治疗的切入点由细胞水平向分子水平过度,提高肿瘤联合治疗的效果,成为肿瘤综合治疗策略。由此应运而生蛋白酪氨酸激酶抑制剂独树一帜,对其研究和评价日趋活跃,本文总结其作用优势和临床评价。方法：采用国内、外文献综述方法。结果及结论：酪氨酸激酶抑制剂疗效确切、特异性强、不良反应和耐药性小,无疑是药学研究领域中的巨大突破。

Clinical Evaluation and Development of Protein Tyrosinase Inhibitor

OBJECTIVE:Due to the development of pharmacol and biotechnology,epidermal growth factor receptor(EGFR)and vascular endothelial growth factor(VEGF)have been regarded as the target sites in the attack against tumor cells,leading to the shifting of drug treatment focus from cellular level to molecular level and the enhancing of curative effect of combined therapy of tumor,thus a combined therapy of tumor has came into being.from which,the tyrosinase inhibitor were produced and which have developed a school of ...